Dosage and Administration. The recommended daily dose in adults or elderly is 100 mg (50 mg every 12 hours). No significant increased benefit can be expected from higher daily doses. Contraindications Hypersensitivity to the active substance or to any of the excipients. Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal. Patients who are pregnant or breast-feeding. In patients with impaired renal function, riluzole is not recommended for use in patients with impaired renal function, as studies at repeated doses have not been conducted in this population Side effects Asthenia, nausea, vomiting, headache, abdominal pain, dizziness, tachycardia, somnolence, oral paraesthesias, neutropenia, elevations in liver function tests. Asthenia, nausea, vomiting, headache, abdominal pain, dizziness, tachycardia, somnolence, oral paraesthesias, neutropenia, elevations in liver function tests. Drug Interactions1 There is no actual data to evaluate interactions with other drugs, however it is thought that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole. Inhibitors of CYP 1A2 (e.g. caffeine, diclofenac, diazepam, TCAs, theophylline and quinolones) could potentially decrease the rate of riluzole elimination, while inducers of CYP 1A2 (e.g. cigarette smoke, rifampicin and omeprazole) could increase the rate of riluzole elimination.
Dosage and Administration. Dosage: _________________________________________________________________________________________________________________________________ Date(s) medication to be given: ___________________________________________________________________________________________________ Times medication to be given: _____________________________________________________________________________________________________ Reasons for medication: ____________________________________________________________________________________________________________ Possible side effects: ________________________________________________________________________________________________________________ Directions for storage: ______________________________________________________________________________________________________________ Name and phone number of the prescribing health care practitioner: ____________________________________________________ Parent and Practitioner Signature Child’s Health Care Practitioner Signature: _________________________________________ Date: ______________________ I, , (parent or guardian—Print name) authorize educators to administer Medication to my child as indicated above. ___________________________________________________________________ Parent/Legal Guardian Signature _________________________ Date Individual Health Care Plan Plan was created by: Plan is maintained by: ___ Parent ___ Doctor or Licensed Practitioner ___ Program’s Health Care Consultant ___ Other: _________________________ ___ Director ___ Assistant Director ___ Child’s Educator ___ Other: ____________________________ Name of Child: Date: Any Changes to the Child’s Health Care Plan? YES (Indicate changes below) NO (updated physician/parent signatures required) Name of chronic health care condition: Description of chronic health care condition: Symptoms: Medical treatment necessary while at the program: Potential side effects of treatment: Name of educators that received training addressing the medical condition: Person who trained the educator (Child’s Health Care Practitioner, Child’s Parent programs Health Care Consultant): Name of Licensed Health Care Practitioner (please print): _______________________________________ Licensed Health Care Practitioner Authorization: _____________________________Date: ______________
Dosage and Administration. Neoral® capsules 10mg, 25mg, 50mg, 100mg or Oral solution 100mg/ml Maintenance dose in adult renal transplant patients: 2-6mg/kg/day (twice daily in divided doses). Dose adjusted according to trough blood-ciclosporin concentration and renal function. The concomitant intake of grapefruit juice has been reported to increase the bioavailability of ciclosporin . xxxx://xxx.xxxxxxxxx.xxx.xx Contraindication Known hypersensitivity to ciclosporin. Concomitant use of tacrolimus. Side Effects All suspected reactions (including those considered not to be serious and even where the causal link is uncertain) should be reported to the CSM. As with all immunosuppressants ciclosporin increases susceptibility to infections. Very common: renal dysfunction, hyperlipidaemia, tremor, headache, and hypertension Common: hyperuricaemia, hyperkalaemia, hypomagnesaemia, paraesthesia, anorexia, nausea, vomiting, abdominal pain, diarrhoea, gingival hyperplasia, hepatic dysfunction, hypertrichosis, muscle cramps, myalgia, fatigue Uncommon: anaemia, thrombocytopenia, signs of encephalopathy or demyelination, convulsions, confusion, disorientation, decreased responsiveness, agitation, insomnia, visual disturbances, cortical blindness, coma, paresis, cerebellar ataxia, allergic rashes, oedema, weight increase Rare: micro-angiopathic haemolytic anaemia, haemolytic uraemic syndrome, menstrual disturbances, gynaecomastia, hyperglycaemia, motor polyneuropathy, pancreatitis, muscle weakness, myopathy Very rare: optic disc oedema including papilloedema with possible visual impairment secondary to Benign Intracranial Hypertension. Drug Interactions – for detailed information refer to the SPC and Appendix 1 in BNF Drugs that decrease ciclosporin levels: Barbiturates, carbamazepine, phenytoin; rifampicin; octreotide; orlistat; hypericum perforatum (St John's Wort); ticlopidine. Drugs that increase ciclosporin levels:Macrolide antibiotics (mainly erythromycin and clarithromycin); ketoconazole, fluconazole, itraconazole; diltiazem, nicardipine, verapamil; metoclopramide; oral contraceptives; danazol; methylprednisolone (high dose); allopurinol; amiodarone; ursodeoxycholic acid; protease inhibitors. References Novartis® Pharmaceuticals UK Ltd. Summary of product characteristics, Feb 2005 xxxx://xxx.xxxxxxxxx.xxx.xx/ Ipswich Hospital. Shared care agreement for the treatment of chronic autoimmune joint & connective tissue disease, Feb 2005 BNF 51, March 2006.
Dosage and Administration. Initial Stabilisation Treatment should be started with 200mg, three times a day and may be continued for 1 week. The dosage should then be reduced to 200mg, twice daily for a further week.
Dosage and Administration. Recommended dose of bicalutamide is one tablet (50 mg) taken once daily.
Dosage and Administration. The dose of Dronedarone is 400mg twice daily and should be taken with meals Treatment with Dronedarone can be initiated in an outpatient setting If a dose is missed, patients should take the next dose at the regular scheduled time and should not double the dose There is no need for a loading dose or for titration. There is no clinically relevant interaction with warfarin, however, since Dronedarone is a P-glycoprotein inhibitor, it increases plasma concentrations of Dabigatran; therefore concomitant use of the two drugs has to be avoided. Treatment with Class I or III antiarrhythmics (such as flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol, amiodarone) must be stopped before starting dronedarone. A washout period of one month is recommended before dronedarone is started for patients currently receiving amiodarone. For patients receiving Dronedarone who are to receive amiodarone a washout period of two weeks is recommended. Contraindications Hypersensitivity to the active substance or to any of the excipients. Second- or third- degree atrioventricular block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker). Bradycardia <50 beats per minute (bpm). Permanent AF with an AF duration of ≥ 6 months (or duration unknown) and attempts to restore sinus rhythm no longer considered by the physician Patients in unstable hemodynamic conditions History of, or current heart failure or left ventricular dysfunction Patients with liver and lung toxicity related to previous use of amiodarone Co-administration with potent cytochrome P 450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefadazone and ritonavir. Medicinal products inducing torsades de pointes such as phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides, Class 1 and III antiarrhythmics. QTc Xxxxxxx interval ≥ 500 milliseconds. Severe hepatic impairment. Severe renal impairment (CrCl <30ml/min) Side Effects Dronedarone is a black triangle drug. Continue to report to the MHRA and the Commission on Human medicines all suspected adverse reactions via the Yellow Card Scheme. Common side effects include diarrhoea, abdominal discomfort, rash, bradycardia, fatigue, asthenia, nausea, vomiting, raised creatinine ( 10% five days after treatment initiation, tubular secretion of creatinine is decreased without affecting GFR) and prolonged QT Interval...
Dosage and Administration. Cellcept 250mg capsules, 500mg tablets or Oral suspension 1g/5ml Dose in adult renal transplant patients: 1g twice daily Contraindications Hypersensitivity to mycophenolate mofetil or mycophenolic acid. Contraindicated in breast-feeding women. For information on use in pregnancy see Summary of Product Characteristics (SPC). Side Effects All suspected reactions (including those considered not to be serious and even where the causal link is uncertain) should be reported to the CSM. xxx.xxxx.xxx.xx/Xxxxxxxxxxxxxxxxx/Xxxxxxxxxxxxxxxxxxxxxxx/xxxxx.xxx As with all immunosuppressants mycophenolate increases susceptibility to infections. The most frequent side effects seen with mycophenolate include neutropenia and gastrointestinal disturbances including diarrhoea, constipation, vomiting and indigestion. Less common side effects include gastrointestinal haemorrhage, hypertension, oedema, hyper- and hypokalaemia, hyperglycaemia, Hypophosphataemia, hypercholesterolaemia, dyspnoea, headache, dizziness, insomnia and tremor. Drug Interactions – for detailed information refer to the SPC and Appendix 1 in BNF. Aciclovir: increased plasma concentrations of aciclovir and mycophenolic acid glucuronide have been observed on concurrent administration of MMF and aciclovir.
Dosage and Administration dosage at two grams per day, taken as two capsules once daily, with or without food;
Dosage and Administration. The recommended dose of denosumab is 60 mg administered as a single subcutaneous injection once every 6 months into the thigh, abdomen or upper arm. Patients must be adequately supplemented with calcium and vitamin D. Renal Impairment No dose adjustment is required Hepatic impairment Denosumab has not been tested in patients with hepatic impairment. Contra-indications / Special precautions Contraindications • Hypocalcaemia • Hypersensitivity to the active substance or to any of the excipients listed Cautions Calcium and Vitamin D supplementation Adequate intake of calcium and vitamin D is important in all patients. Precautions for use Hypocalcaemia It is important to identify patients at risk for hypocalcaemia. Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. Clinical monitoring of calcium levels is recommended before each dose and, in patients predisposed to hypocalcaemia within two weeks after the initial dose. If any patient presents with suspected symptoms of hypocalcaemia during treatment calcium levels should be measured. Patients should be encouraged to report symptoms indicative of hypocalcaemia. In the post-marketing setting, severe symptomatic hypocalcaemia has been reported, with most cases occurring in the first weeks of initiating therapy, but it can occur later. Skin Infections Patients receiving denosumab may develop skin infections (predominantly cellulitis) leading to hospitalisation. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of cellulitis. Osteonecrosis of the Jaw (ONJ) ONJ has been reported rarely in clinical studies and in the post marketing setting in patients receiving denosumab at a dose of 60 mg every 6 months for osteoporosis. ONJ has been reported commonly in clinical studies in patients with advanced cancer treated with denosumab at the studied dose of 120 mg administered monthly. Known risk factors for ONJ include previous treatment with bisphosphonates, older age, poor oral hygiene, invasive dental procedures (e.g. tooth extractions, dental implants, oral surgery), and co-morbid disorders (e.g. pre-existing dental disease, anaemia, coagulopathy, infection), smoking, a diagnosis of cancer with bone lesions, concomitant therapies (e.g., chemotherapy, antiangiogenic biologics, corticosteroids, radiotherapy to head and neck). It is important to evaluate patients for risk factors for ONJ before starting treatment. A dental exami...
Dosage and Administration. Treatment for 7 days from initial onset of symptoms Prophylaxis Adults 100 mg orally twice daily 100 mg orally twice daily Adults with severe hepatic dysfunction, renal failure (CrCl 10 mL/min) and elderly nursing home patients 100 mg orally once daily 100 mg orally once daily Children age 1-9 years 6.6 mg/kg per day, but not exceeding 150 mg (divided into 2 doses) 5 mg/kg per day, but not exceeding 150 mg Children age 10 years 100 mg orally twice daily 100 mg orally twice daily
